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Abstract  29 
Background: The aim of the study was to explore practitioner-patient interactions and patient 30 
responses when using QRISK®2 or JBS3 cardiovascular disease (CVD) risk calculators. Data were from 31 
video-recorded NHS Health Check (NHSHC) consultations captured as part of the UK RIsk 32 
COmmunication (RICO) study; a qualitative study of video-recorded NHSHC consultations from 12 33 
general practices in the West Midlands, UK. Participants were those eligible for NHSHC based on 34 
national criteria (40-74 years old, no existing diagnoses for cardiovascular-related conditions, not on 35 
statins), and practitioners, who delivered the NHSHC. 36 
Method: NHSHCs were video-recorded. 128 consultations were transcribed and analysed using 37 
deductive thematic analysis and coded using a template based around Protection Motivation 38 
Theory.  39 
Results: Key themes used to frame the analysis were Cognitive Appraisal (Threat Appraisal, and 40 
Coping Appraisal), and Coping Modes (Adaptive, and Maladaptive). Analysis showed little evidence 41 
of CVD risk communication, particularly in consultations using QRISK®2. Practitioners often missed 42 
opportunities to check patient understanding and encourage risk- reducing behaviour, regardless of 43 
the risk calculator used resulting in practitioner verbal dominance. JBS3 appeared to better promote 44 
opportunities to initiate risk-factor discussion, and Heart Age and visual representation of risk were 45 
more easily understood and impactful than 10-year percentage risk.  However, a lack of effective 46 
CVD risk discussion in both risk calculator groups increased the likelihood of a maladaptive coping 47 
response.  48 
Conclusions: The analysis demonstrates the importance of effective, shared practitioner-patient 49 
discussion to enable adaptive coping responses to CVD risk information, and highlights a need for 50 
effective and evidence-based practitioner training.   51 
Trial registration: ISRCTN ISRCTN10443908. Registered 7th February 2017 52 















Classification: Restricted  
Background 67 
Cardiovascular disease (CVD) is the leading cause of death worldwide, accounting for one in four 68 
deaths in England (1). NHS Health Check (NHSHC) is a national programme designed to screen CVD 69 
risk, facilitate early diagnosis and reduce health inequalities (2). All eligible adults, aged 40-74 years, 70 
should be invited for NHSHC where CVD risk is assessed based on several risk factors (e.g., blood 71 
pressure and cholesterol). Best practice guidance suggests a patient should be given appropriate CVD 72 
risk management advice following effective risk communication (3). However, information on the 73 
nature and quality of the consultation is scarce. Insight is limited to patient and practitioner 74 
experiences (4), which do not provide a complete understanding of patient-practitioner interactions 75 
within the NHSHC.  76 
Communicating risk is challenging (6) and differs according to patient understanding, numerical 77 
literacy,  and personality traits (7). Further, emotional responses to risk and the resulting influence on 78 
health behaviour varies between patients (8–11). If delivered sub optimally, risk communication can 79 
increase anxiety and reduce confidence in health professionals (12). Effective risk communication can 80 
improve knowledge, empower and create autonomy (13–15). Within NHSHC, 10-year percentage is 81 
calculated and communicated to patients using a prediction algorithm, QRISK®2 [with current 82 
transference to QRISK®3 (16)], which is populated from new and pre-existing data within the patient’s 83 
record. However, most younger eligible adults are predisposed to a lower CVD risk which can lead to 84 
false reassurances (17,18), misinterpretation (5,19–22), and poor patient recall and confusion (23).  85 
The 2014 JBS risk calculator (JBS Board, 2014)  includes Heart Age (25–28) and 10-year percentage 86 
risk, but primarily focuses on lifetime risk of CVD events through CVD event-free survival (Table 1). It 87 
also presents information using multiple visual displays (Table 1) (6) and a function to manipulate the 88 
scores to show how risk-factor modification affects overall risk (e.g., smoking cessation). Whilst there 89 
is some evidence to suggest that lifetime risk, Heart Age and visual displays may be more effective 90 
during the communication of risk (27–36), until recently, no research has compared the efficacy of 91 
JBS3 and QRISK®2 for communicating risk in NHSHC.  92 
 93 



































QRISK®2 ✓ ✓ ✓  ✓      
QRISK®2 
+Informatica 
✓ ✓ ✓  ✓ ✓  ✓  ✓ 
JBS3 ✓  ✓ ✓ ✓  ✓ ✓ ✓ ✓ 
 95 
Patient-practitioner interactions are complex (37,38), yet application of theories such as Protection 96 
Motivation Theory (PMT; 37) have shown how fear of threat can translate in to health-protective 97 
behaviour (39). Within PMT, the intention to engage in health-protective behaviour is influenced by 98 
an individual’s cognitive appraisals (Fig 1). CVD risk information presented in an NHSHC can feed into 99 
such appraisals, either threat appraisal (risk of CVD), or coping appraisal (consequences of undertaking 100 
positive behaviour change).  101 
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 102 
Fig 1. Protection Motivation Theory model adapted to proposed study context (39) 103 
 104 
Threat appraisal focuses on the source of the threat (CVD risk) and evaluates the probability of a 105 
maladaptive response (i.e., behaviours that inhibit patients’ ability to adjust to the threat). It considers 106 
patients’ perceived severity of CVD risk, the consequences of CVD, perceived vulnerability to future 107 
CVD and intrinsic and extrinsic rewards for not addressing CVD risk [i.e., perceived benefits of not 108 
acting to manage or reduce risk (maladaptive response)]. Coping appraisal evaluates the adaptive 109 
coping responses available to the patient to deal with the threat (i.e., evaluation of ways to reduce 110 
CVD risk). This includes patients’ perceptions of self-efficacy to engage in adaptive coping, 111 
practitioners’ promotion of self-efficacy through individualisation, perceived response efficacy of 112 
adaptive coping, and response cost of adaptive coping (Figure 1). Both are influenced by intrapersonal 113 
(e.g., prior experience of both positive (adaptive) and negative (maladaptive) behaviours) and 114 
environmental variables (e.g., persuasive communication) (41). For NHSHC, PMT highlights the 115 
practitioners’ key role in providing information on CVD risk whilst taking into account a patients’ 116 
experience, priorities and beliefs to encourage engagement in risk-reducing behaviours (42).  117 
The RIsk COmmunication in NHSHC (RICO) study involved analysis of video-recorded NHSHC 118 
consultations (43). Analysis of quantitatively characterised content of consultations found that 119 
compared with JBS3 consultations, those using QRISK®2 were shorter, more verbally dominated by 120 
practitioners and involved less discussion of CVD risk (44). This provided the first insight from objective 121 
data on the nature and content of NHSHC consultations, with comparison between risk calculators. 122 
But the need for more in-depth qualitative analysis, to explore the quality of interactions around CVD 123 
risk and how this differs by CVD risk calculator, was clear. This paper uses deductive thematic analysis 124 
on a sample of video-recorded consultations, from the RICO study, which aimed to: explore how 125 
practitioners use QRISK®2 and JBS3 to communicate CVD risk in the consultation; explore how patients 126 
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The RICO study sought to explore the perception and understanding of CVD risk from both patients 132 
and practitioners, when using the JBS3 or QRISK®2 calculator, the practitioners’ associated advice or 133 
offer of treatment and the patients’ response. Information regarding the overall study, including 134 
recruitment and data collection is available (43). In this report, we focus on qualitative deductive 135 
analysis of video-recorded NHSHC consultations.  136 
 137 
Participants and Recruitment  138 
A detailed description of patient and public engagement along with participant and practice 139 
recruitment is available elsewhere (44). To summarise; data were collected from general practices 140 
(n=12) located in the West Midlands of England (Jan-17 to Feb-19), supported by the Clinical Research 141 
Network West Midlands. Practices were matched in pairs, based on deprivation, and assigned to usual 142 
practice (communicated CVD risk using QRISK®2) or intervention (communicated CVD risk using JBS3). 143 
Two practices in the QRISK®2 group used Informatica (supplementary software within in the NHSHC 144 
template that includes Heart Age and risk manipulation similar to JBS3; Table 1); data were included 145 
in the analysis as this was felt representative of ‘usual care’. Quotations from the transcripts from 146 
these practices are referred to as ‘QRISK®2+Informatica’. Only patients who were eligible for an 147 
NHSHC, based on national criteria, were included in the study (45). Postal invitations included a 148 
participant information sheet and were stratified based on gender, age and ethnicity for each practice. 149 
Practitioners were already employed by the practice (8 Health Care Assistants (HCAs), 6 Practice 150 
Nurses, 1 Sister) and all but one practitioner already had experience of delivering NHSHC as part of 151 
their job role (a HCA who was new to NHSHC delivery; 1-2 weeks prior to study commencement). 152 
In total, 175 video-recorded NHSHCs were conducted (range 6.8 to 38 minutes), reduced to 173 153 
following screening of data (JBS3=100; QRISK®2=73; practitioner error resulted in 2 exclusions). To 154 
define the sample for qualitative analysis, a further 21 Health Checks were excluded for reasons 155 
including: projected (not actual) risk score communicated (n=7), no discussion of risk (n=2), no 156 
communication of lifetime risk (n=4), incorrect use of JBS3 (n=6), insufficient use of English language 157 
(n=2). Of the remaining sample (n=154), 64 Health Checks included communication of CVD risk using 158 
QRISK®2. Therefore, 64 NHSHC using JBS3 were identified, matched on patients’ gender, ethnicity and 159 
CVD risk score (Table 2), giving a sample of 128 for analysis.  160 
 161 
Procedure 162 
Practices video-recorded NHSHCs, communicating CVD risk using QRISK®2 or JBS3 (following both 163 
patient and practice consent). All consultation dialogue was transcribed verbatim. 164 
 165 
Analysis 166 
Data were analysed using deductive thematic analysis (46,47) using a coding template based around 167 
Protection Motivation Theory (PMT; 37) (Supplementary Material 1). Each transcript was uploaded to 168 
QSR International's NVivo 12 qualitative data analysis software (51). This allowed for interpretation of 169 
how QRISK®2 and JBS3 were used to communicate risk in the context of PMT components (e.g., verbal 170 
persuasion, influencing patient prior beliefs and priorities; and how patients respond, which will 171 
reflect the nature of their appraisal within the consultation).  172 
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Initially, 14 transcripts were inductively coded independently by two Caucasian female researchers, 173 
experienced in qualitative research, a senior researcher (LC; DPsych) and research associate (VR; 174 
MSc). The senior researcher (LC) had previous research experience related to children’s healthy 175 
eating whilst the research associate (VR) had previous research experience in risk communication in 176 
NHSHC. This was to check the application of PMT to NHSHC consultations and agree coding between 177 
the researchers. Following inductive coding, 13 new codes were added to the framework (e.g., 178 
medical history, clarification of results). The final version of the coding template shows how 179 
elements of the PMT were classified including code definitions and examples from the NHSHC 180 
consultations (Supplementary Material 2). The remaining 114 transcripts were individually coded by 181 
LC and VR; two in every 20 transcripts were independently dual-coded to check reliability using 182 
Kappa coefficients for each NVivo node within the PMT framework (i.e., 19th, 20th, 39th, 40th, 59th, 183 
60th etc). Reliability ranged from .48 to .71 over the five reliability checks conducted, indicating fair 184 
to good reliability (52). Data saturation was considered reached at the point of completion of coding.  185 
Subsequent analysis of codes was led by SF (Researcher; MSc) (supported by SG, CG, NE and VR) to 186 
identify codes for key elements of the PMT model, splitting the consultations into two groups 187 
(QRISK®2 andJBS3). Specific parts of transcripts that illustrated the practitioner communicating CVD 188 
risk to the patient and patient responses were identified. These related to Cognitive Appraisal (Threat 189 
Appraisal, and Coping Appraisal), and Coping Modes (Adaptive, and Maladaptive). The focus of the 190 
present analysis was the consultation time spent communicating CVD risk (across sample 191 
approximately 1.7 (±0.83) minutes) (44), to explore similarities and differences between the two 192 
calculators under investigation. Most patients said little in response to CVD risk information. 193 
Therefore, where there was evidence of two-way dialogue, we present quotations that best illustrate 194 
risk communication and subsequent patient response.  195 
 196 
Results 197 
Deductive thematic analysis was conducted on 128 video-recorded NHSHC consultations. Patients 198 
were approximately matched by gender, age and ethnicity. Those in the QRISK®2 group were 199 
marginally younger (Table 2).  200 
 201 
Table 2. Characteristics of patients included in analysis 202 
  QRISK®2  JBS3 
Gender    
 Female 32 32 
 Male 32 32 
 Total 64 64 
    
Age    
 40-54 34 21 
 55-64 17 20 
 65-74 13 23 
 Total 64 64 
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Ethnicity    
 White British (WBRI) 58 56 
 Black Asian and Minority Ethnic (BAME) 6 8 
 Total 64 64 
    
CVD Risk    
 Low % 43 43 
 Med-high % 21 21 
 Total 64 64 
 203 
Results of the deductive thematic analysis demonstrate how practitioners communicated risk using 204 
either QRISK®2 or JBS3. They also present patients’ responses to the communication of risk, allowing 205 
for evaluation of the two calculators. Each quote is coded to denote which risk calculator was used, 206 
the consultation identifier, patient gender and age. 207 
 208 
Cognitive Appraisal 209 
Threat appraisal 210 
Threat appraisal was the most commonly identified element of the PMT model. It was observed in all 211 
consultations, although less frequently in JBS3 consultations (coded 584 times; average 212 
9/consultation) compared to QRISK®2 consultations (coded 634 times; average 10/consultation).   213 
Once presented with a QRISK®2 score, patients acknowledged their risk level, but their understanding 214 
of 10-year percentage risk was unclear. For example, one asked ‘is that percentage of risk alright?’. 215 
Generally, the risk score was acknowledged with a single word response, such as ‘yeah’ or ‘okay’, 216 
impeding practitioners’ ability to gauge patient understanding and classification of response for this 217 
analysis. Heart Age aided patient understanding of CVD risk, resulting in questions such as: “… so really 218 
what can I do about that?  I mean I know it is all estimated.” Such questions reflected a level of 219 
understanding of the score and intention to engage in risk-reducing behaviour. Several patients 220 
expressed surprise at their risk. Below, the patient appeared to question how the score was calculated 221 
as they perceived themselves to be healthier than the outcome suggested, leading to some mistrust. 222 
They also made two references to being ‘fitter’ than the risk score indicated, which was not addressed 223 
by the practitioner:   224 
P I thought I was fitter than that though. 225 
HP (Laughter) You are doing good exercises,  226 
P But I was fitter than that though… 227 
HP OK, so the health years, so on average expect to survive is 80 for yourself without a heart 228 
attack or a stroke, yeah?  And then your risk of a heart attack or stroke in the next ten years is 229 
15%, so you do need to look after yourself, because we would say that is a medium risk. 230 
P Yes 231 
HP So wouldn’t say it is too high or low, but a medium to high. 232 
P OK 233 
HP OK, and then that’s what it looks like so from now until there, that’s the last one the chance of 234 
surviving without a heart attack. 235 
P That’s estimated? 236 
HP This is estimated, we don’t know what’s going to happen you might be even longer. 237 
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P So about 94 I might snuff it? 238 
(JBS3, 11_028, Male, 58) 239 
 240 
By overlooking the patient’s surprise and perhaps focusing on the process of NHSHC, the patient 241 
momentarily shut down until they were presented with their CVD event-free survival age. The 242 
concept, included within JBS3, prompted some misunderstanding among patients and practitioners. 243 
This was perceived by some patients as an estimate of life expectancy. 244 
Practitioners provided little follow-up risk score explanation when using QRISK®2 or JBS3.  245 
HP  Right, this is the screening I was telling you about.  I will just print that out for you.  So your 246 
risk of any heart disease is 15%. 247 
P  Yeah, which is not very high.  248 
HP It does increase with age.  If it is above 10% we then pass it on for them to have a look at it 249 
and they will be able to decide when to have your next health check which should be three 250 
years or one year.  Obviously next time you come in any results you’ve got in the red tend to 251 
up your risk and they tend to up your Heart Ageas well.  So when you come in next time if your 252 
blood pressure is back down, and obviously it could be less so…  Your Heart Age has come up 253 
as 66. 254 
P  Well I am 66 this year. 255 
HP  Yes, yes, so it is quite near isn’t it? 256 
Yes.  So, for example, if you were a smoker and that was in the red that would put your Heart 257 
Age at 75.  So the only one we have got in the red really is that one cholesterol… 258 
P  It’s only marginal though isn’t it 259 
(QRISK®2+Informatica, 2_016, Male, 65) 260 
 261 
Above, the patient was identified as medium-high risk, but the practitioner did not elaborate on the 262 
severity or implications, leaving the patient’s interpretation of their risk score as “not very high”. This 263 
was compounded when the patient received their Heart Age. The practitioner did not address the 264 
patient’s misinterpretation of the severity of their risk nor explain why their results are conflicting, 265 
again perhaps focussing more so on the consultation process than the patient. This led the patient to 266 
dismiss their elevated cholesterol as “only marginal”. The absence of active listening skills was 267 
recurrent across both groups making it difficult to gauge patient understanding.   268 
Although limited, there was more evidence of active practitioner-patient engagement in conversation 269 
regarding threat of CVD in the JBS3 group following risk score manipulation (e.g., practitioners visually 270 
showed patients that a reduction in blood pressure, could lower their Heart Age): 271 
HP … so obviously your blood pressure is not too bad, that is fine where it is at 128, but your 272 
cholesterol, so ideally we like that to be below 5.  So if you could get it below 5, so lets put it 273 
down to 4.8, you can see that automatically that it brings your risk down to 1.8% 274 
P Oh I see yes 275 
HP … improves your life expectancy slightly, and probably brings your Heart Age down a year.  So 276 
it is just you know showing that it can and obviously, the lower you can keep these factors that 277 
you influence, for longer, the better quality of life and life expectancy there is… your risk is 278 
going to increase slightly with age.  So it is about trying to moderate those other factors. 279 
P So what impact does exercise have on that? 280 
HP It has quite a significant impact on your cholesterol, it does help your cholesterol a lot.  We 281 
know that it helps because that increases your good cholesterol, which can help increase the 282 
balance so, that can help with it as well. 283 
P So what’s the normal range that is seen for HDL cholesterol? 284 
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HP HDL can be anything from sort of 1.1 to about 2.5, you don’t get much over, I can't say I have 285 
seen many, I have seen a few.  But your cholesterol could be anything down to you know 3.5. 286 
P OK and really bad would be? 287 
HP 6 or 7’s, so would be sort of … 288 
P Oh OK – so 5.6 is yeah it is edging up isn’t it? 289 
(JBS3, 7_020, Male, 45) 290 
 291 
The patient evaluated the threat and sought information to facilitate their appraisal. Whilst positive, 292 
this exchange again demonstrated misunderstanding of CVD event-free survival age as life expectancy, 293 
this time from the practitioner. The visual impact of demonstrating how CVD risk can be reduced 294 
through risk factor modification (e.g., cholesterol, smoking status) aided patient understanding and 295 
realistic threat appraisal. There were fewer examples of active engagement during discussion of the 296 
CVD risk score within QRISK®2 consultations, which may be due to the inability to show risk factor 297 
modification when using the calculator. 298 
 299 
Coping appraisal 300 
References to coping appraisal were more common among JBS3 (60, 94%) than QRISK®2 consultations 301 
(55, 86%). Communication of risk in JBS3 consultations were not observed in the same way as QRISK2; 302 
with most focussed on facilitators of adaptive coping (i.e., risk-reducing changes that patients could 303 
make): 304 
HP Erm and then this gives you your healthy year’s outlook, so based on your current lifestyle your 305 
risk of a heart attack or a stroke in the next 10 years is coming out at 2.4 %.   We aim for 306 
peoples risk to be below 10% so that’s… 307 
P Yeah. 308 
HP …absolutely fine and on average you expected to survive to an age of 84 without a heart attack 309 
or stroke, so brilliant.  So as I say your blood pressure pretty good as it is you not going get 310 
that much lower. 311 
P No. 312 
HP Diet wise would you say you got a pretty good diet do you know the sorts of… 313 
P We sort of grow our own vegetables and fruit and stuff like that… 314 
HP Yeah. 315 
P …so erm I mean we eat reasonably healthy. 316 
(JBS3, 7_044, Female, 54) 317 
 318 
Following communication of the risk score, the practitioner moved on to ways the patient could 319 
maintain a low risk through identification of eating behaviours, suggesting that whilst practitioners 320 
(from both groups) spent little time talking about the CVD risk score, the additional risk information 321 
available in JBS3 may have helped to facilitate more risk factor discussion between the patient and 322 
practitioner than when using QRISK®2.  323 
Discussions around response costs for adaptive coping (i.e. perceived costs associated with a 324 
recommended behaviour) related to use of statins or blood pressure medication were only observed 325 
in seven JBS consultations (11%) and, not any QRISK®2 consultations.  326 
HP Obviously we’ve tried them, and they haven’t agreed with you. 327 
P I tried the ***17,34 statin 328 
HP Yeah, and there are other statins we can discuss and obviously benefits of those they can 329 
reduce your cholesterol obviously and we can reduce your risk of cardiovascular disease so it 330 
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might be worth having a think about and if you want to just discuss that further or a different 331 
type of statin… 332 
P All they did was it affected my reflux and it made the reflux worse 333 
HP Yeah  334 
P So 335 
HP Yeah  336 
P I was on that and an Aspirin – I did the aspirin first and then … 337 
HP Yeah, but it was affecting you.  I mean it might be worth a having another… err you know a 338 
think about whether you wanted to erm take that, because  obviously it would lower your 339 
cholesterol, obviously add to  a healthier heart erm and reduce that risk of cardiovascular 340 
disease, but  then  obviously we’ll not gonna push that onto you, err it is something you can 341 
talk to myself, one of  the doctor’s once you have had time to think erm and they can advise 342 
or XXX the prescribing nurse, because  they can prescribe, you know talk about you know 343 
what’s best, which statin would be best, and not all statins agree with everybody but there 344 
might be one out there that actually has a better erm compatibility with yourself OK? 345 
P Yeah 346 
HP How do you feel about what I have told you today? 347 
P I would consider it. 348 
(JBS3, 8_177, Male, 71) 349 
 350 
Here, the patient’s prior engagement with statins as a response cost was discussed between the 351 
patient and the practitioner, leading to a re-evaluation of the medical intervention by the patient. 352 
However, the patient’s concern regarding their previous experience of taking statins was not well 353 
addressed. The practitioner appeared to interrupt the patient to repeat the benefits of statins. The 354 
perceived cost of taking statins also provided motivation to adopt risk-promoting behaviours: 355 
HP  But well done! 356 
P I am pleased about that yes. 357 
HP That’s really good, no I am very pleased with you because that’s really good.  And where you 358 
were at 10% just before, it is now 5%, so you have halved the risk in that time.  So that’s really 359 
good.  So it shows it can be done. 360 
P Yeah, yeah and that’s what I would rather do than taking tablets, 361 
HP Of course 362 
P I would rather think, no I know what’s wrong, I will deal with it in time. 363 
(QRISK®2+Informatica, 12_055, Female, 64) 364 
 365 
In a previous NHSHC (conducted 5 years prior), the patient identified what was wrong and showed 366 
accountability for making health-related behavioural changes, “I will deal with it”. However, 367 
opportunities to discuss facilitators of adaptive coping were sometimes missed by practitioners: 368 
HP I look at your [total: HDL cholesterol] ratio and your ratio is good.  But just to keep a little eye 369 
on it, maybe they will test it again in a year’s time. You probably won't be due this Health 370 
Check, because your risk is only 3%, which is low.  It will increase as you age, so your Health 371 
Check wouldn’t be due again for five years, but you could probably have your cholesterol done 372 
in about a year, with you know normal bloods taken out of your arm. Erm your Heart Age, 373 
because you got such results in the green, your Heart Age has come up less than your actual 374 
age, but that’s with the two years added on from being an ex-smoker. 375 
P So is it possible that I could get that even lower, if my cholesterol came down a lot. 376 
HP Well we will have a look now, I will play about with it.  So if you had never smoked at all, your 377 
Heart Age would be 45.  If you were still smoking, it could be 51.  So being an ex-smoker tends 378 
to add two years, so with your cholesterol, it could be brought down to 46. 379 
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P Massively yeah. 380 
 (QRISK®2+Informatica, 2_077, Male, 48) 381 
 382 
The patient above attempted to understand how their risk could be reduced. The practitioner did not 383 
engage with this to encourage the risk-reducing behaviour or discuss ways to reduce cholesterol. 384 
Rather, they proceeded to talk about the impact of previous smoking status (which is unmodifiable) 385 
on CVD risk. Whilst references to coping appraisal were more common among JBS3 consultations, 386 
again practitioners in both groups appeared to focus more on the consultation process than the 387 
patient. 388 
 389 
Coping Modes 390 
Maladaptive Coping 391 
Maladaptive coping was classified when the patient appeared to negatively engage in risk 392 
management discussion with the practitioner and was dismissive of suggestions (e.g., patient believes 393 
they have a sufficiently healthy lifestyle and dismisses discussion about change). As noted, patient 394 
responses to risk information were often limited to single words. Where context allowed, apparent 395 
non-engagement and minimal verbal responses from patients were also interpreted as maladaptive 396 
coping responses when the risk information communicated by the practitioner did not provoke a 397 
response from the patient (i.e., a monosyllabic response). Maladaptive coping was identified in 49 398 
(77%) QRISK®2 consultations (coded 139 times; average 3/consultation), compared to 40 (62.5%) JBS3 399 
consultations (coded 110 times; average 3/per consultation). Below, the practitioner briefly 400 
communicates QRISK®2 before moving on to Heart Age (using Informatica):  401 
HP Yeah this is the screening I was telling you about.  So, your risk is 9%  402 
P Right 403 
HP Which is your key risk for you over the heart disease and diabetes and stroke risk 404 
P And heart disease 405 
HP As you, as you age your risk does seem to increase, erm any results that you’ve got in the red 406 
tend to push up your Heart Age slightly 407 
P Aha 408 
HP So if we can get the results out of the red and back into the green, that can reduce that one 409 
down 410 
P Right OK 411 
HP So for example, being an ex-smoker actually puts 2 years onto your Heart Age there. 412 
P Yeah 413 
HP So would be its 66 and it would be 66 if you never smoked at all. 414 
P Right 415 
HP Erm if you were still smoking it would be 73. 416 
P Oh my gosh 417 
HP Your Heart Age has come up as 71 – you are 69. Any results you have got in the red do tend to 418 
increase your Heart Age. It is just that one cholesterol one that was in the red.   419 
(QRISK®2+Informatica, 2_001, Female, 66) 420 
 421 
Sometimes maladaptive responses to the 10-year percentage risk score could be prompted into a 422 
more positive response through communication of Heart Age. The brief exchange prior to the 423 
communication of Heart Age may have also suggested that the practitioner was less confident in 424 
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discussing absolute risk, a recurrent observation. If practitioners cannot clearly explain the meaning 425 
of a patient’s percentage risk score to confer understanding, subsequent discussion/actions regarding 426 
risk management may be undermined.  427 
Minimal engagement following communication of the risk score was also identified in JBS3 428 
consultations: 429 
HP OK.  And your blood pressure being under 82 but that’s fine everything is OK with that.  Now, 430 
on average what they’re saying is that your risk of a heart attack or stroke in the next 10 years 431 
is 15%, again, that is down to the fact that you smoke. 432 
P Hm 433 
HP OK.   434 
P Sigh 435 
HP And to expect to survive till the age of 78 without a heart attack or a stroke OK.  And if we have 436 
a look at the next, this one, just reiterates its this, but if I changed it to… say if you didn’t smoke 437 
OK and we went to the next your Heart Age would then become equal with your age. 438 
P Hm hm 439 
HP And your risks in… of a heart attack or stroke in the next 10 years comes down to 9.6% and 440 
your actual survival to the age of 83 without a heart attack or a stroke OK and that reiterates 441 
it in that as well. 442 
P Hm hm 443 
HP OK so that’s the difference. 444 
P Hm hm 445 
P  Hm hm  446 
HP  OK. Erm  447 
P  Cough  448 
HP  So it gives you food for thought.  449 
P  Hmm hmm. You haven’t told me anything I didn’t already know. 450 
(JBS3, 1_181, Male, 65) 451 
 452 
The practitioner did not encourage the patient to quit smoking nor did they explore any experience 453 
with previous attempts and therefore were unlikely to promote intention to change behaviour. With 454 
an added pressure of time within NHSHC consultations, adherence to the process of completing the 455 
NHSHC may result in patients being passive recipients of information. As shown above (and 456 
throughout), the practitioner delivered the information presented on the screen without asking 457 
questions to check understanding or provide context. This resulted in little response from the patient 458 
which may be indicative of deference to the practitioner’s health knowledge and is, again, evidence 459 
of power imbalance.  460 
Negative engagement in discussion of risk factor management was also evident following the 461 
suggestion of statin use: 462 
HP What we do tend to say if you risk is above 10%, obviously I don’t know whether the doctors 463 
have ever discussed a statin with you? 464 
P I don’t see the point, I mean if I am going to live to 83, I am quite happy to live to 83.  465 
HP So it's just about being aware that we know that taking a statin can help reduce your overall 466 
risk, so it's one that sort of we usually advise that … 467 
P If we do this next time and I don’t know, it was 04 [last cholesterol check], and we are now in 468 
2018, so what does that mean, it could be another 12 to 14 years [for the next Health Check]? 469 
HP Well I do normally try and do these every five years, so yeah. 470 
P So yes, if it is hugely worse 471 
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HP Yeah 472 
P … in five years, I will consider it. 473 
(JBS3, 7_012, Male, 70) 474 
 475 
Again, the patient misinterpreted CVD event-free survival age and suggested that their risk was not 476 
severe enough to consider medical intervention in the short-term; only if it was “hugely worse” in the 477 
next NHSHC. This was another example of a missed opportunity for the practitioner to question the 478 
patient’s understanding of their risk and potential false reassurance provided by the 10-year 479 
percentage risk score.  480 
 481 
Adaptive Coping 482 
Adaptive coping was classified when the patient appeared to positively engage with discussion of 483 
interventions to manage CVD risk; apparently listened to and engaged in the consultation and 484 
accepted what was being said/suggested. Adaptive coping was identified in 58 QRISK®2 (91%) 485 
consultations with (310 codes; average 5/consultation) and 55 JBS3 (86%) consultations (328 codes; 486 
average 6/consultation). The frequency of occurrences overall and per consultation were similar 487 
between the two groups for adaptive coping in medical interventions [39 QRISK®2 (61%) consultations 488 
and 116 codes (average 3/consultation); 42 JBS3 (66%) consultations and 142 codes (average 489 
3/consultation)] and lifestyle changes [11 QRISK®2 (17%) consultations and 15 codes (average 490 
1/consultation); 20 JBS3 (31%) consultations and 32 codes (average 2/consultation)]. A number of 491 
patients showed intentions to change behaviour as a result of their CVD risk.  492 
HP So your ratio is 3.5.  So this is the screening I was telling you about.  So your risk is 3%. That 493 
will increase as you age. 494 
P Yeah 495 
HP And obviously if we can, perhaps with your smoking, it has pushed your Heart Age up to 48, 496 
and your age is 41.  Because that is the only result you have got in the red.  Because all your 497 
other results are really good, they are in the green. 498 
P They are really good, so I need to … 499 
HP Yeah, so if you had never smoked at all, your Heart Age would be aged 40. 500 
P I think I need to do something about that don’t I? 501 
(QRISK®2+Informatica, 2_122, Male, 41) 502 
 503 
Here is another example of how Heart Age changed the way the patient responded to the information 504 
presented. Whilst a positive response was received, little time was allowed to respond before the 505 
practitioner moved on. Giving time for the patient to check their understanding with the practitioner 506 
may have provided opportunity for the patient to increase their confidence in actively engaging with 507 
coping behaviours. Another example of positive engagement during the discussion of risk was also 508 
identified in another practice: 509 
HP OK that’s good.  Err let’s see your key risk.  510 
P If I know what weight so I can just try to change my life. 511 
HP Yeah, yeah it would be good if you can cut down and, and lose a bit of the weight err what was 512 
it 13.8.  So it’s only a little higher it should ideally be below 10% is what we want so 13.8 is a 513 
bit high but it is because of, because of your weight.  OK you don’t smoke you don’t drink 514 
alcohol so that’ all good, but your waist is a bit big as well. 515 
P Yeah 516 
HP Your waist is erm it’s 112 let’s have a look. 517 
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P Around my tummy around here. 518 
HP Yeah let’s have a look.  So your waist is 44 inches. 519 
P And that’s this bit here. 520 
(QRISK®2, 3_259, Male, 57) 521 
 522 
The patient above engaged in the information presented about their risk and suggested a need for 523 
weight management, somewhat reinforced by the practitioner. However, the interaction was 524 
disjointed, which may be a result of the practitioner’s need to complete all elements of the NHSHC 525 
and attending to what the patient is saying, creating a barrier for adaptive coping. Whilst scarce, a 526 
successful strategy for supporting adaptive coping used by one practitioner was to ask the patient to 527 
reflect on the risk information they had received, prompting consideration of action needed:   528 
HP  So average survival free of heart attack or stroke is 84.1 years OK?  So how do you feel about 529 
that? 530 
P Oh I will make more of an effort to lose some weight. 531 
(JBS3, 1_154, Female, 70) 532 
 533 
The approach adopted by the practitioner encouraged the patient to express their immediate reaction 534 
to their CVD risk, which gave the patient time to evaluate their action and show intention to change 535 
their behaviour. This was a rare example of the PMT in action; showing connection between risk 536 
information and the patient’s intention to change her behaviour, helping to redress the power 537 
imbalance evident in most consultations across both groups. It also demonstrated the significant role 538 
the practitioner plays in ensuring risk communication is delivered effectively regardless of the risk 539 




We report the first qualitative data from 128 video-recorded NHSHCs to explore how practitioners use 544 
QRISK®2 and JBS3 to communicate CVD risk in the consultation, and how patients respond to risk 545 
information. An ecologically valid approach was used to compare usual practice (QRISK2) with use of 546 
JBS3 following basic introductory training to familiarise practitioners with the tool and features to use. 547 
This allowed a realistic study of how practitioners would use JBS3 if it was made available, without 548 
additional risk communication training, which is generally not provided for NHSHC practitioners (4,53).  549 
Main findings in relation to our aims were, first, that components of the PMT including threat 550 
appraisal, facilitators of and response costs to adaptive coping were coded more frequently in 551 
consultations using JBS3 (compared with QRISK2). This suggests that JBS3 may provide more 552 
opportunities to initiate risk factor discussion than QRISK2, possibly due to the risk factor modification 553 
function. Second, CVD event-free survival age communicated in JBS3, was misunderstood by both 554 
patients and practitioners. Third, patients presented with a QRISK®2 score acknowledged their risk 555 
level, but it was unclear whether they understood 10-year percentage risk (or trusted the basis and 556 
relevance to them). Visual presentations of risk and Heart age, found in JBS3 (not typically 557 
communicated within standard practice systems - although can be generated in QRISK®2), appeared 558 
more impactful and aided patient understanding, compared with QRISK®2. This is in line with evidence 559 
that Heart Age is easier to understand than 10-year percentage risk (30,54) and visual displays are 560 
preferable for promoting risk-reducing behaviour (31).  561 
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Regardless of the risk calculator used and despite the recognised importance of risk communication 562 
in both the NHSHC best practice guidance (3) and competence framework (55), there was little 563 
discussion of CVD risk. This was particularly marked in QRISK®2 consultations. Practitioners often 564 
simply relayed the risk score, without discussing the implications of the risk for the patient or what 565 
they could do about it. Equally, most patients offered minimal responses to the risk information, often 566 
acknowledging with a single word. Practitioners may have avoided confirming patient understanding 567 
if they felt unable to explain the risk scores in more detail or the pressure of time may have prevented 568 
further exploration at the expense of the quality of risk communication. This supports evidence that 569 
patients and practitioners struggle to understand CVD risk and some practitioners lack confidence in 570 
communicating the risk score (4,18–21) leading to poor patient recall of CVD risk, confusion (22) and 571 
misunderstanding.  572 
There was an apparent absence of active listening by practitioners who frequently missed cues from 573 
patients who were unclear about their risk score. Active listening involves making a conscious effort 574 
to focus on what is being said rather than passively ‘hearing’ the message, and leads to improved 575 
levels of patient satisfaction and greater adherence to treatment options (56). By not providing 576 
additional information to patients that would allow them to appraise their risk, practitioners are 577 
limiting the opportunity for patients to show intent to engage in risk reducing behaviours, thus 578 
encouraging a maladaptive coping response. Best practice guidance (3) recommends that 579 
practitioners use motivational interviewing (MI) to encourage adherence to recommended treatment 580 
(57). Motivational interviewing is a person-centred approach to promote discussion with patients to 581 
resolve ambivalence (58). There was little to no evidence of MI techniques in our 128 NHSHC.  582 
Limited patient responses and poor listening skills, leading to practitioner dominance, were inferred 583 
from quantitative analysis of the complete RICO study cohort [n=173 (44)]. These were confirmed 584 
here, with evidence of missed opportunities to discuss patients’ intentions to behaviour change. 585 
Missing these opportunities risks undermining the purpose of the NHSHC; without discussion of 586 
intervention practitioners are unlikely to encourage patients to commit to engaging in risk-reducing 587 
behaviours. The demands on practitioners to complete all aspects of an NHSHC within a limited time 588 
could lead to prioritisation of process over patient engagement. The resulting practitioner-dominated 589 
consultations are less patient-centred, and would be expected to lead to low patient and practitioner 590 
satisfaction (59–62), and poor patient outcomes, such as adherence to clinical recommendations and 591 
health-promoting behaviour (63). Where there was talk of risk-reducing behaviour, JBS3 appeared 592 
more effective than QRISK®2 in promoting discussion of facilitators for adaptive coping, perhaps due 593 
to additional functionality (i.e., manipulation of risk).  This suggests that other methods of 594 
communicating risk may be more suitable to promote discussion around risk-reducing behaviour.  595 
 596 
Implications for Practice 597 
The NHSHC programme is an ambitious non-communicable disease prevention programme, the 598 
largest of its kind (4). An evidence-based review of NHSHC is underway to maximise the programme’s 599 
benefit in the next decade, with likely changes to the universal offer of in-person consultations in 600 
primary care (64). Whilst changes to delivery are inevitable, elements of the programme will still 601 
require practitioner-patient consultation. Our findings show that certain functions of JBS3 are useful 602 
for communicating CVD risk to patients, and also highlighted important implications for NHSHC 603 
practice in general: 604 
• There is a clear training need among NHSHC practitioners. There is an expectation that 605 
practitioners ‘should be trained in communicating the risk score and results to the client’ and 606 
 
Classification: Restricted  
that ‘methods, such as motivational interviewing techniques, should engage clients in person-607 
centred conversations about their own reasons for change’ (55) (p21). Yet it is difficult for 608 
practitioners to meet these requirements without necessary training and ongoing support. 609 
Here, these skills were generally not evident and we know from previous work that 610 
practitioners responsible for delivering NHSHC generally receive little (or no) training in CVD 611 
risk communication and motivational interviewing (22,65,66).  612 
• Alongside training, there is also a need to prioritise the quality of interaction over the process 613 
of the consultation. Increasing the overall appointment length or, perhaps more feasible, 614 
streamlining the components of NHSHC would give practitioners more time to engage 615 
patients in dialogue regarding their CVD risk and its management. The minimal response from 616 
patients during NHSHC consultations made it difficult for us (and practitioners) to gauge 617 
patient understanding and intentions for health-promoting behaviour. 618 
Positive outcomes were identified when practitioners checked patient understanding, relayed 619 
information in a way that was meaningful to the patient (e.g. Heart age) and asked for patient 620 
feedback around the CVD risk score. Practices included in the sample allocated 15-30 minutes per 621 
Health Check, but our quantitative evidence showed consultations lasted as little as 6.8 minutes (44). 622 
There is clearly a need to provide additional support for practitioners. Measures to make consultations 623 
more patient-focused and give practitioners the flexibility to allow engagement in dialogue should be 624 
explored.  625 
 626 
Strengths and Limitations  627 
This is the first qualitative analysis to explore how risk is communicated and how patients respond 628 
during video-recorded NHSHC consultations, including comparison of QRISK®2 and JBS3 CVD risk 629 
calculators. Strengths include video-recording of NHSHCs across a diverse range of practices stratified 630 
by deprivation, with stratified sampling of patients, a comprehensive coding approach and a large 631 
sample (for qualitative analysis). Limitations are recognised: 632 
• The use of QRISK®2+Informatica may have enhanced these consultations. To maintain 633 
ecological validity of ‘usual practice’, patients from these practices were included in the main 634 
analysis and has not altered our conclusions.  635 
• Incorrect use of JBS3 (e.g., including communication of CVD event-free survival) resulted in 636 
the exclusion of several consultations which may have biased our comparisons in favour of 637 
JBS3.  638 
• Sparse discussion specifically around the risk score and subsequent patient responses made 639 
it difficult to apply the PMT framework effectively (the theoretical framework required 640 
researchers to classify patient responses as either positive or negative). Thus, a third ‘neutral’ 641 
classification was added to the framework to account for monosyllabic responses (see 642 
Supplementary Material 2 for examples). Yet following the PMT, the new category still needed 643 
to be classified as one of the two coping modes (i.e., adaptive or maladaptive). Moreover, 644 
follow-up interviews with patients and practitioners as part of the RICO study, will be analysed 645 
to further explore their experiences, perceptions and understanding of CVD risk and related 646 
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Analysis of video-recorded NHSHC consultations showed sparse communication of CVD risk, 650 
particularly in consultations supported by QRISK®2. Where risk was communicated, patient responses 651 
were minimal and practitioners missed opportunities to check patient understanding and encourage 652 
risk-reducing behaviour. JBS3 appeared to better promote opportunities to initiate risk-factor 653 
discussion and Heart Age and visual representation of risk were more easily understood and impactful 654 
than QRISK®2. The apparent lack of effective CVD risk discussion in both groups resulted in 655 
misunderstandings, practitioner-dominated discussion and increased likelihood of a maladaptive 656 
coping response. The NHSHC programme is currently the largest CVD prevention initiative in England. 657 
Whilst an evidence-based review of NHSHC is underway (58), with likely changes to programme 658 
delivery, face to face consultations are necessary to deliver key elements of NHSHC. The analysis 659 
presented demonstrates the importance of effective, shared practitioner-patient discussion for 660 
enabling adaptive coping responses, only achievable through solid practitioner understanding of the 661 
nature of the information being shared and through effective training to deliver this information to 662 
patients (66).  663 
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